The current COVID19 pandemic showcases a critical need to accelerate the development and validation of quality diagnostic products for COVID-19. To support this effort, PATH, a global health non-profit, has created a growing biorepository of qualified clinical samples to support and accelerate the development and validation of quality in-vitro diagnostics.
Roger Peck cataloging the first set of samples in the biorepository.
The Washington COVID-19 biorepository now includes convalescent plasma to accelerate the development of antibody assays. Convalescent plasma samples allow manufacturers to assess the performance of several designs and prototypes under development. By running multiple replicates of these relatively accessible specimens on each prototype, diagnostics developers can generate large amounts of performance data allowing for better assessment of the technology.
Click here to read more.